tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH
查看詳細走勢圖
27.120USD
+0.310+1.16%
收盤 12/26, 16:00美東報價延遲15分鐘
1.26B總市值
11.50本益比TTM

Amphastar Pharmaceuticals Inc

27.120
+0.310+1.16%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.16%

5天

+1.95%

1月

-0.88%

6月

+17.00%

今年開始到現在

-26.96%

1年

-28.95%

查看詳細走勢圖

操作建議

Amphastar Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名30/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價31.71。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Amphastar Pharmaceuticals Inc評分

相關信息

行業排名
30 / 158
全市場排名
86 / 4563
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 6 分析師
買入
評級
31.714
目標均價
+21.93%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Amphastar Pharmaceuticals Inc亮點

亮點風險
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
業績高增長
公司營業收入穩步增長,連續3年增長46.69%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入731.97M美元
估值合理
公司最新PE估值11.50,處於3年歷史合理位
機構加倉
最新機構持股33.97M股,環比增加0.05%
HACAX持倉
明星投資者HACAX持倉,最新持倉276.00股

Amphastar Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Amphastar Pharmaceuticals Inc簡介

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
公司代碼AMPH
公司Amphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
網址https://amphastar.com/

常見問題

Amphastar Pharmaceuticals Inc(AMPH)的當前股價是多少?

Amphastar Pharmaceuticals Inc(AMPH)的當前股價是 27.120。

Amphastar Pharmaceuticals Inc 的股票代碼是什麼?

Amphastar Pharmaceuticals Inc的股票代碼是AMPH。

Amphastar Pharmaceuticals Inc股票的52週最高點是多少?

Amphastar Pharmaceuticals Inc股票的52週最高點是39.010。

Amphastar Pharmaceuticals Inc股票的52週最低點是多少?

Amphastar Pharmaceuticals Inc股票的52週最低點是20.385。

Amphastar Pharmaceuticals Inc的市值是多少?

Amphastar Pharmaceuticals Inc的市值是1.26B。

Amphastar Pharmaceuticals Inc的淨利潤是多少?

Amphastar Pharmaceuticals Inc的淨利潤為159.52M。

現在Amphastar Pharmaceuticals Inc(AMPH)的股票是買入、持有還是賣出?

根據分析師評級,Amphastar Pharmaceuticals Inc(AMPH)的總體評級為買入,目標價格為31.714。

Amphastar Pharmaceuticals Inc(AMPH)股票的每股收益(EPS TTM)是多少

Amphastar Pharmaceuticals Inc(AMPH)股票的每股收益(EPS TTM)是2.358。
KeyAI